Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Apr;32(3):272-9.
doi: 10.1016/j.urolonc.2013.09.003. Epub 2013 Dec 8.

The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research

Benjamin T Ristau  1 , Denise S O'Keefe  2 , Dean J Bacich  1
Affiliations
Review

The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research

Benjamin T Ristau et al. Urol Oncol. 2014 Apr.

Abstract

Objective: Despite a multitude of detection and treatment advances in the past 2 decades, prostate cancer remains the second leading cause of deaths due to cancer among men in the United States. Technological evolution and expanding knowledge of tumor biomarkers have invigorated exploration in prostate cancer therapeutics. Prostate-specific membrane antigen (PSMA) was one of the first prostate cancer biomarkers successfully cloned. Since then, it has been characterized as the prototypical cell-surface marker for prostate cancer and has been the subject of intense clinical inquiry. In this article, we review the relevant research in PSMA on the 20th anniversary of its cloning.

Methods and materials: A PubMed search using the keywords "prostate-specific membrane antigen" or "glutamate carboxypeptidase II" provided 1019 results. An additional 3 abstracts were included from scientific meetings. Articles were vetted by title and abstract with emphasis placed on those with clinically relevant findings.

Results: Sixty articles were selected for inclusion. PSMA was discovered and cloned in 1993. Its structure and function were further delineated in the ensuing decade. Consensus sites of expression in normal physiology are prostate, kidney, nervous system, and small intestine. PSMA has been implicated in the neovasculature of several tumors including urothelial and renal cell carcinomas. In prostate cancer, expression of PSMA is directly related to the Gleason grade. PSMA has been tested both in imaging and therapeutics in a number of prostate cancer clinical trials. Several recent approaches to target PSMA include the use of small molecule inhibitors, PSMA-based immunotherapy, RNA aptamer conjugates, and PSMA-targeted prodrug therapy. Future study of PSMA in prostate cancer might focus on its intracellular functions and possible role in tumor neurogenesis.

Conclusions: Twenty years from its discovery, PSMA represents a viable biomarker and treatment target in prostate cancer. Research to delineate its precise role in prostate carcinogenesis and within the therapeutic armamentarium for patients with prostate cancer remains encouraging.

Keywords: Cancer therapeutics; Folate; Prostate cancer; Prostate-specific membrane antigen; Tumor markers.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Article selection for review
Figure 2
Figure 2
Confocal microscopy after immunohistochemical staining for PSMA on LNCaP cells with GFP-marked mitochondria. Green=mitochondria, Red=PSMA, Blue=nuclei
See this image and copyright information in PMC

References

    1. D’Amico AV, Whittington R, Malkowicz B, et al. Endorectal magnetic resonance imaging as a predictor of biochemical outcome after radical prostatectomy in men with clinically localized prostate cancer. The Journal of urology. 2000 Sep;164(3 Pt 1):759–763. - PubMed
    1. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. The New England journal of medicine. 2009 Mar 26;360(13):1320–1328. - PubMed
    1. Miles BJ, Shalev M, Aguilar-Cordova E, et al. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Human gene therapy. 2001 Nov 1;12(16):1955–1967. - PubMed
    1. Carter HB, Albertsen PC, Barry MJ, et al. Early Detection of Prostate Cancer: AUA Guideline. The Journal of urology. 2013 May 6; - PMC - PubMed
    1. Moyer VA, Force USPST Screening for prostate cancer: U. S. 2012 Preventive;157(2):120–134. - PubMed